QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=BAEA13BB19F380CD60064C818B6AA95D;jsessionid=EA2456C126E478739072922D7CD92E40;jsessionid=E693DD6F558AAA1CB72C58E85592F896;jsessionid=7E6244966A56C3D86A347510E105B4BB;jsessionid=5C97F818B3717AE665DDCD81ACCAEBB2 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=BAEA13BB19F380CD60064C818B6AA95D;jsessionid=EA2456C126E478739072922D7CD92E40;jsessionid=E693DD6F558AAA1CB72C58E85592F896;jsessionid=7E6244966A56C3D86A347510E105B4BB;jsessionid=5C97F818B3717AE665DDCD81ACCAEBB2